Selank
Tuftsin-derived heptapeptide — GABA-A subunit expression research reagent
Select pack size
Buy nowDelivery in 4 to 7 days. Tracked shipping, discreet packaging — tracking number sent by email once your parcel is on its way.
Delivery in 4 to 7 days · tracked, discreet packaging
Card, Apple Pay, SEPA bank transfer or crypto · 3D-Secure
Lot-specific COA
HPLC >99% — Janoshik analysis on request
Plain, discreet packaging
No contents named on the outer label
Delivery in 4 to 7 days
Tracked shipping across the EU, EEA and Switzerland
About Selank
Updated June 2026In stock now. Selank 5 mg from $35, >99% HPLC-verified purity, ships in 4 to 7 days with a lot-specific COA on request. For research use only.
Selank is a synthetic heptapeptide derived from the immunomodulator tuftsin, studied for anxiolytic and neurocognitive effects. Supplied as lyophilized powder; reconstitute with bacteriostatic water before in-vitro work. Selank is a research reagent only — not for human or veterinary use.
Selank (TP-7) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed at the Institute of Molecular Genetics (IHF) of the Russian Academy of Medical Sciences in Moscow under the leadership of Nikolai Myasoedov. The peptide is based on the sequence of Tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunomodulatory tetrapeptide first identified in 1970 by Victor Najjar at Tufts University. The additional D-Arg-Pro-Gly-Pro C-terminal extension to Tuftsin significantly increases the molecule's metabolic stability and extends the biological half-life from a few minutes to several hours. Selank's mechanism of action is multimodal and encompasses three central pathways: First, Selank modulates the GABAergic system by influencing GABA-A receptor subunit expression, producing anxiolytic action without sedative effects — a fundamental difference from benzodiazepines, which act directly as GABA-A agonists. Second, Selank influences expression of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) in the hippocampus and prefrontal cortex, promoting neuroplastic processes. Third, Selank acts via regulation of enkephalin degradation through inhibition of enkephalinase (neprilysin), modulating endogenous opioid signaling. Clinical studies at IHF (Zozulya et al., Bulletin of Experimental Biology and Medicine, 2008) with over 300 subjects show significant anxiolytic properties in standardized tests (Hamilton Anxiety Rating Scale, Spielberger STAI) without sedative action, cognitive impairment or dependence potential. Additionally, studies by Ershov et al. (Doklady Biological Sciences, 2009) document immunomodulatory effects via regulation of IL-6 and interferon gene expression, with Selank significantly modulating the expression of 38 immune-system genes. In Russia, Selank has been approved as an intranasal medicinal product since 2008.
Specifications
- In Russian Phase II/III studies in 300+ subjects, anxiolytic scores changed without reported sedation or dependence signals (Zozulya et al., 2008)
- Modulation of the GABAergic system via GABA-A receptor subunit expression (not direct agonism)
- Induction of BDNF and NGF expression in hippocampus and prefrontal cortex — neuroplasticity promotion
- Immunomodulatory effects: regulation of 38 immune-system genes (Andreeva et al., 2014)
- Approved in Russia since 2008 as an intranasal formulation for generalized anxiety disorders
- Inhibition of enkephalinase (neprilysin) — modulation of endogenous opioid signaling
- Phase II/III clinical trials with 300+ subjects: significant reduction on the Hamilton anxiety scale
- Comparable anxiolytic efficacy to Phenazepam (benzodiazepine) without dependence risk
- Based on Tuftsin — immunomodulatory tetrapeptide discovered in 1970 by Najjar at Tufts University
- Regulation of IL-6 and interferon gene expression — bridge between anxiolysis and immunomodulation
Research context
Development and clinical studies summarized in Zozulya et al., "Selank (TP-7): Anxiety-Relieving Peptide with Nootropic and Immunostimulatory Properties", Bulletin of Experimental Biology and Medicine, Volume 145, Pages 61–63 (2008), DOI: 10.1007/s10517-008-0010-x. This work documents the Phase II/III clinical evaluation in over 300 subjects. BDNF and NGF expression documented in Narkevich et al., "Effects of Selank on Content of Monoamines and Their Metabolites in the Brain of BALB/c and C57BL/6 Mice", Neuroscience Letters, Volume 442, Pages 120–125 (2008). Immunomodulatory effects comprehensively described in Ershov et al., "Selank Modifies the Expression of Cytokines and Immunity Genes", Doklady Biological Sciences, Volume 427, Pages 379–381 (2009). GABAergic modulation and enkephalinase inhibition described in Seredenin & Gudasheva, "Selank and Its Analogs: Structural and Functional Studies", CNS & Neurological Disorders Drug Targets, Volume 17, Pages 224–232 (2018), DOI: 10.2174/1871527317666180206120316. Genome-wide expression analysis of immunomodulatory effects in Andreeva et al. (Molecular Biology, 2014), where 38 immune-system genes were identified as Selank-responsive. Clinical comparison studies with Phenazepam (benzodiazepine) show comparable anxiolytic efficacy without dependence potential (Kozlovskii & Danchev, Experimental and Clinical Pharmacology, 2003).
Storage & handling
Temperature
-20°C (lyophilized) / 2–8°C (reconstituted)
Conditions
Protect from direct light and moisture
Shelf life
18 months (lyophilized, sealed vial)
Reconstitution of Selank
Solvent
Bacteriostatic water (0.9% benzyl alcohol)
Volume
1 mL
Concentration
5 mg/mL at 1 mL
Step-by-step
- 1Allow the vial and bacteriostatic water to reach room temperature (15–20 minutes).
- 2Use an alcohol swab to disinfect the rubber stoppers of both vials.
- 3Draw 1 mL of bacteriostatic water using a sterile 1 mL graduated syringe.
- 4Place the needle against the side of the vial and let the water run slowly down the inner wall.
- 5Gently swirl the vial or roll it between your palms. Selank usually dissolves quickly and completely. Never shake.
- 6Visually inspect the clear solution for particulates. Do not use if cloudy.
- 7Store reconstituted Selank at 2–8°C and use within 14 days.
- 8Disinfect the rubber stopper and use a fresh sterile syringe for each aliquot drawn for assay.
Frequently asked questions
What is Selank and how does it work?
Selank (TP-7) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy. It is based on Tuftsin and modulates the GABAergic system, BDNF expression and enkephalin degradation.
Does Selank have dependence potential?
Published Russian studies in 300+ subjects reported anxiolytic scores without sedation or dependence signals. That is a description of the literature, not a safety claim for this reagent: Selank is supplied for research use only and has not been evaluated for human use in the EU or US.
How is Selank reconstituted and stored?
Reconstitute the lyophilized powder with bacteriostatic water. Store lyophilized at -20°C, reconstituted at 2–8°C. Protect from light and moisture. In Russia, Selank is also approved as a nasal spray formulation.
Can Selank be combined with Semax?
In research, Selank and Semax are often investigated in parallel, as they have different, potentially complementary mechanisms of action. Selank focuses on GABAergic modulation, Semax on BDNF stimulation and neuroprotective pathways.
Is Selank available for research?
Yes, Selank is available as a research peptide. It is not an approved medicinal product and may be used only for scientific in-vitro research.
Order Selank
From $35 · Purity >99%· Delivery in 4 to 7 days
Research reference
Read the Selank research guide
Dosage math, reconstitution, COA checks and protocol context for Selank.
